Thermodynamic Dissection of the Binding Energetics of Proline-rich Peptides to the Abl-SH3 Domain: Implications for Rational Ligand Design

Journal of Molecular Biology

Volumn 336, Issue 2, 2004, Pages 527-537

  Palencia, Andrés ^a   Cobos, Eva S ^a   Mateo, Pedro L ^a   Martínez, Jose C ^a   Luque, Irene ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Binding energetics; Calorimetry; Ligand design; SH3 domains; Water mediated interactions

Indexed keywords

ABELSON KINASE; ALANYLPROLYLSERYLTYROSYLSERYLPROLYLPROLYLPROLYLPROLYLPROLINE; LIGAND; PEPTIDE; PROTEIN; PROTEIN SH3; UNCLASSIFIED DRUG; WATER;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING KINETICS; CALORIMETRY; CONFORMATIONAL TRANSITION; ENERGY TRANSFER; ENTHALPY; ENTROPY; HYDROGEN BOND; IONIZATION; LIGAND BINDING; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTON TRANSPORT; THERMODYNAMICS;

EID: 0742306902     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2003.12.030     Document Type: Article

References (46)

1. Kay B.K., Williamson M.P., Sudol M. The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J. 232:2000;231-241.
2. Hiipakka M., Poikonen K., Saksela K. SH3 domains with high affinity and engineered ligand specificities targeted to HIV-1 Nef. J. Mol. Biol. 293:1999;1097-1106.
3. Cheng H., Hoxie J., Parks W.P. The conserved core of human immunodeficiency virus type 1 Nef Is essential for association with Lck and for enhanced viral replication in T-lymphocytes. Virology. 264:1999;5-15.
4. Vidal M., Gigoux V., Garbay C. SH2 and SH3 domains as targets for anti-proliferative agents. Crit. Rev. Oncol. Hematol. 40:2001;175-186.
5. Demirov D.G., Ono A., Orenstein J.M., Freed E.O. Overexpression of the N-terminal domain of TSG-101 inhibits HIV-1 budding by blocking late domain function. Proc. Natl Acad. Sci USA. 99:2002;955-960.
6. Martin-Serrano J., Zang T., Bieniasz P.D. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 sites of particle assembly to facilitate egress. Nature Med. 7:2001;1313-1319.
7. Lee K.-Y., Yoon J.H., Kim M., Roh S., Lee Y.-S., Seong B.-L., Kim K. A dipalmitoyl peptide that binds SH3 domain, disturbs intracellular signal transduction, and inhibits tumor growth in vivo. Biochem. Biophys. Res. Commun. 296:2002;434-442.
8. Murakami Y., Fukazawa H., Kobatake T., Yamagoe S., Takebe Y., Tobiume M., et al. A mammalian two-hybrid screening system for inhibitors of interaction between HIV Nef and the cellular tyrosine kinase Hck. Antiviral Res. 55:2002;161-168.
9. Hiipakka M., Huotari P., Manninen A., Renkema G.H., Saksela K. Inhibition of cellular functions of HIV-1 Nef by artificial SH3 domains. Virology. 286:2001;152-159.
10. Nguyen J.T., Turck C.W., Cohen F.E., Zuckermann R.N., Lim W.A. Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors. Science. 282:1998;2088-2092.
11. Pisabarro M.T., Serrano L. Rational design of specific high-affinity peptide ligands for the Abl-SH3 domain. Biochemistry. 35:1996;10634-10640.
12. Luque I., Todd M.J., Gomez J., Semo N., Freire E. The molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis. Biochemistry. 37:1998;5791-5797.
13. Velazquez-Campoy A., Luque I., Freire E. The application of thermodynamic methods in drug design. Thermochim. Acta. 380:2001;217-227.
14. Sawyers C.L. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell. 1:2002;13-15.
15. Brasher B.B., Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory sites. J. Biol. Chem. 275:2000;35631-35637.
16. Brasher B.B., Roumiantsev S., Van Etten R.A. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene. 20:2001;7744-7752.
17. Barila D., Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nature Genet. 18:1998;280-282.
18. Azam M., Latek R.R., Daley G.Q. Mechanisms of STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112:2003;831-843.
19. Velazquez-Campoy A., Luque I., Todd M.J., Milutinovich M., Kiso Y., Freire E. Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor. Protein Sci. 9:2000;1801-1809.
20. Wittekind M., Mapelli C., Farmer B.T. II, Suen K., Goldfarb V., Tsao J., et al. Orientation of peptide fragments from Sos proteins bound to the N-terminal SH3 domain of Grb2 determined by NMR spectroscopy. Biochemistry. 33:1994;13531-13539.
21. Ferreon J.C., Hilser V.J. The effect of the polyproline II (PPII) conformation on the denatured state entropy. Protein Sci. 12:2003;447-457.
22. Renzoni D.A., Pugh D.J.R., Siligardi G., Das P., Morton C.J., Rossi C., et al. Structural and thermodynamic characterization of the interaction of the SH3 domain from Fyn with the proline-rich binding site on the p85 subunit of PI3-Kinase. Biochemistry. 35:1996;15646-15653.
23. Wang C., Pawley N.H., Nicholson L.K. The role of backbone motions in ligand binding to c-Src SH3 domain. J. Mol. Biol. 313:2001;873-887.
24. Baker B.M., Murphy K.P. Evaluation of linked protonation effects in protein binding using isothermal titration calorimetry. Biophys. J. 71:1996;2049-2055.
25. Gomez J., Freire E. Thermodynamic mapping of the inhibitor site of the aspartic protease endothiapepsin. J. Mol. Biol. 252:1995;337-350.
26. Luque I., Freire E. Structural stability of binding sites: consequences for binding affinity and allosteric effects. Proteins: Struct. Funct. Genet. Suppl. 4:2000;63-71.
27. Luque I., Freire E. Structural parameterization of the binding enthalpy of small ligands. Proteins: Struct. Funct. Genet. 49:2002;181-190.
28. Renzoni D.A., Zvelebil M.J.J.M., Lundback T., Ladbury J.E. Exploring uncharted waters: water molecules in drug design strategies in structure-based drug design. Ladbury J.E., Connely P.E. Structure-based Drug Design. Thermodynamics, Modeling and Strategy. 1997;161-184 Springer, Berlin.
29. Viguera A.R., Arrondo J.L.R., Musacchio A., Saraste M., Serrano L. Characterization of the interaction of natural proline-rich peptides with five different SH3 domains. Biochemistry. 33:1994;10925-10933.
30. Covell D.G., Wallquist A. Analysis of protein-protein interactions and the effects of amino acid mutations on their energetics. The importance of water molecules in the binding epitope. J. Mol. Biol. 269:1997;281-297.
31. Bhat T.N., Bentley G.A., Boulot G., Greene M.I., Tello D., Dall'Acqua W., et al. Bound water molecules and conformational stabilization help mediate an antigen-antibody associated. Proc. Natl Acad. Sci. USA. 91:1994;1089-1093.
32. Wang Y.X., Freedberg D.I., Wingfield P.T., Stahl S.J., Kaufman J.D., Kiso Y., et al. Bound water molecules at the interface between the HIV-1 protease and a potent inhibitor, KNI-272, determined by NMR. J. Am. Chem. Soc. 118:1996;12287-12290.
33. Wang H., Ben-Naim A. A possible involvement of solvent-induced interactions in drug design. J. Med. Chem. 39:1996;1531-1539.
34. Pisabarro M.T., Serrano L., Wilmanns M. Crystal structure of the Abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions. J. Mol. Biol. 281:1998;513-521.
35. Lim W.A., Richards F.M., Fox R.O. Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains. Nature. 372:1994;375-379.
36. Feng S., Chen J.K., Yu H., Simon J.A., Schreiber S.L. Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. Science. 266:1994;1241-1247.
37. Kuriyan J., Cowburn D. Modular peptide recognition domains in eukariotic signaling. Annu. Rev. Biophys. Biomol. Struct. 26:1997;259-288.
38. Cordier F., Wang C., Grzesiek S., Nicholson L.K. Ligand-induced strain in hydrogen bonds of the c-Src SH3 domain detected by NMR. J. Mol. Biol. 304:2000;497-505.
39. Vijayakumar M., Qian H., Zhou H.X. Hydrogen bonds between short polar side chains and peptide backbone: prevalence in proteins and effects on helix-forming propensities. Proteins: Struct. Funct. Genet. 34:1999;497-507.
40. Kelly M.A., Chellgren B.W., Rucker A.L., Troutman J.M., Fried M.G., Miller A.F., Creamer T.P. Host-guest study of left-handed polyproline II helix formation. Biochemistry. 40:2001;14376-14383.
41. Peranen J., Rikkonen M., Hyvonen M., Kaairainen L. T7 vectors with modified T7lac promoter for expression of proteins in Escherichia coli. Anal. Biochem. 236:1996;371-373.
42. Musacchio A., Saraste M., Wilmanns M. High-resolution crystal structures of tyrosine kinase SH3 domains complexed with proline-rich peptides. Nature Struct. Biol. 1:1994;546-551.
43. Gill S.C., Von Hippel P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182:1989;319-326.
44. Lee B., Richards F.M. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55:1971;379-400.
45. Fukada H., Takahashi K. Enthalpy and heat capacity changes for the proton dissociation of various buffer components in 0.1 M potassium chloride. Proteins: Struct. Funct. Genet. 33:1998;159-166.
46. Christensen J.J., Hansen L.D., Izatt R.M. Handbook of Proton Ionization Heats and Related Thermodynamic Quantities. 1976;Wiley, New York.